Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Silicon containing DOAI

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20130045948AZOCYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE - Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof,02-21-2013
20100035839MEROCYANINE DERIVATIVES - Disclosed are merocyanine derivatives which correspond to the formula (I), wherein L02-11-2010
20080214500Injectable cement composition for orthopaedic and dental use - The present invention relates to ceramic precursor powder compositions and chemically bonded ceramic (CBC) materials, Ca-aluminate and/or calcium silicate, and a composite biomaterial with prolonged shelf time of the precursor, suitable for orthopaedic applications with improved injectability. The present invention also relates to a method of manufacturing said cured material, bioelements, implants, or drug delivery carrier materials made by said cured material, a kit comprising the ceramic precursor powder and hydration liquid, as well as the use of said ceramic precursor powder and hydration liquid, or said cured material, for orthopaedic and dental applications.09-04-2008
20120184509Compounds as TRVP1 Blockers, Pharmaceutical Compositions and Medical Uses Thereof - A kind of new compounds, and their pharmaceutically acceptable salts, and hydrates are disclosed. The pharmaceutical composition thereof is also provided. And also are the medical uses of the compounds, pharmaceutically acceptable salts, hydrates and the pharmaceutical composition for treating the TRPV1-mediate diseases.07-19-2012
20120184508PYRAZOLO PYRIMIDINES - Compounds of formula07-19-2012
20100160256INDAZOLE COMPOUNDS - Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.06-24-2010
20100152135COSMETIC KIT COMPRISING REACTIVE SILICONE COMPOUNDS AND A GLOSSY OIL - The invention relates to a cosmetic kit comprising at least two separately-packaged cosmetic compositions, -the kit comprising at least one silicone compound X, at least one silicone compound Y and, optionally, at least one catalyst, -with the proviso that the compounds X and Y—and the catalyst when present—are not simultaneously in one of said compositions, -said compounds X and Y being able to react together by a hydrosilylation reaction when the catalyst is present or by condensation reaction, when they are brought into contact with one another, -one at least of the first and second compositions comprising at least one glossy oil, -said compounds X and Y and said glossy oil, and their respective amounts, being such that the average gloss of the deposit comprising the two compositions is greater than or equal to 60 out of 100. Lastly the invention relates to a method of making-up keratin materials that involves applying the compounds X and Y and the glossy oil.06-17-2010
20110195929COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS - Described are various compounds and methods for the treatment of flaviviral infections. In particular, alkaloids and imino sugars in arabinose and/or lyxose stereochemical configuration with antiflaviviral activity are described.08-11-2011
20110195930PYRIDINE DERIVATIVE OR ITS SALT, PESTICIDE CONTAINING IT AND PROCESS FOR ITS PRODUCTION - To provide a novel pesticide. The present invention provides a pesticide which contains, as an active ingredient, novel pyridine derivative represented by the formula (I) or its salt: wherein R08-11-2011
20100087394Compositions Containing Betaine and Hydrophobic Silica - A free-flowing, substantially dry-to-the-touch, particulate composition comprises (A) finely particulate hydrophobic silicone-treated silica having a surface area of from 80 to 300 m04-08-2010
20130085119AGENT FOR THE TREATMENT OF SKIN CONDITIONS - Disclosed are methods of treatment and compositions containing at least one non-volatile silicone oil in combination with at least one spreading agent for use in the treatment of skin conditions in mammals typified by scales, plaques and scabs and associated with punctiform bleeding during the removal of scales, plaque or scabs. Preferred conditions are selected from the group consisting of seborrheic dermatitis, psoriasis, and cradle cap wherein the incidence of punctiform bleeding and formation of bloody tear points on the skin during removal of the scales is diminished or prevented.04-04-2013
20090325900FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF - The present invention provides a compound useful as an agent for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides a fused heterocyclic derivative represented by the following general formula (I), a pharmaceutical composition containing the same, a medicinal use thereof and the like. In the formula (I), ring A represents 5-membered cyclic unsaturated hydrocarbon or 5-membered heteroaryl; R12-31-2009
20100144672PYRIMIDINYL PYRAZOLES AS INSECTICIDES AND PARASITICIDE ACTIVE AGENTS - The present invention relates to pyrimidinylpyrazoles and their use as insecticides, and also to processes for their preparation and to compositions comprising such arylpyrazoles.06-10-2010
20100069330Pharmaceutical Compositions and Methods for Preparing and Using Lipophilic Organosulfur Cell Proliferation Inhibitors - Novel compositions of lipophilic organosulfur compounds, their preparation and use in methods for treating disease are described. Silicon confers lipophilicity that can enhance the penetration of the silicon derivative compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics. The organosilyl group provides compounds having improved pharmacokinetics. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, polymorphic forms, crystalline forms or an amorphous form, pharmaceutical compositions and methods for treatment of diseases, maladies or conditions. Also disclosed are processes for making such compounds as well as intermediates useful in such processes.03-18-2010
20100075924DUTPASE INHIBITORS - Deoxyuridine derivatives of the formula03-25-2010
20130079302N-[(HET)ARYLALKYL)] PYRAZOLE(THIO)CARBOXAMIDES AND THEIR HETEROSUBSTITUTED ANALOGUES - The present invention relates to fungicidal N-[(het)arylalkyl)]pyrazolecarboxamide or thiocarboxamide and their heterosubstituted analogues, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.03-28-2013
20090275532COSMETIC COMPOSITION COMPRISING AN OIL - The present invention relates to a cosmetic composition for making up or caring for the skin in the form of a water-in-oil emulsion comprising an aqueous phase and at least 15% by weight, relative to the total weight of the composition, of a fatty phase comprising at least one liquid fatty phase having at least one non-volatile fraction, the said liquid fatty phase comprising at least one dry oil chosen from oils with a viscosity of less than or equal to 10 Cps, a surface tension of between 21 and 31 mN/m and an evaporation rate of less than 0.002 mg/cm2/minute, the said dry oil being present in the emulsion in a content ranging from 55% to 100% by weight relative to the total weight of the non-volatile fraction of the liquid fatty phase, the said liquid fatty phase being such that the calculated weight ratio of the liquid fatty phase remaining in the composition after 10 minutes of drying, to the initial liquid fatty phase, ranges from 0.75 to 1. The invention also relates to the use of the said composition for obtaining a uniform makeup and/or a makeup that does not transfer.11-05-2009
20100041627COMPOSITIONS COMPRISING POLYMERIC EMULSIFIERS AND METHODS OF USING SAME - Provided are compositions comprising a polymeric emulsifier, a hydrophobic agent, a wetting agent having at least one sulfonate group and at least one base-neutralizable carboxylic acid group, and a hydrophilic particulate material. Also provided are methods of mitigating diaper dermatitis using the composition, and methods of promoting the benefits associated with the compositions.02-18-2010
20100130446NITROGEN-CONTAINING FIVE-MEMBERED HETEROCYCLIC COMPOUND - The present invention provides a compound represented by the formula (I):05-27-2010
20130035310Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels - The present invention relates to piperidine and piperazine phenyl sulfonamides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including for example the treatment of pain.02-07-2013
20090156554P13-KINASES - New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases.06-18-2009
20090156553PIPERAZINE COMPOUNDS WITH A HERBICIDAL ACTION - The invention relates to the use of piperazine compounds of formula (I) or the agriculturally useful salts of piperazine compounds of formula (I) as herbicides, the variables in formula (I) being defined as cited in the claims and the description.06-18-2009
20090156552TOPICAL DELIVERY OF PHTHALOCYANINES - The invention relates to topical pharmaceutical compositions comprising a phthalocyanine, wherein a diamagnetic metal ion moiety is either coordinated or covalently bound to the phthalocyanine core. The invention also relates to methods for destroying cancer tissue, precancerous cells, photo-aged cells, damaged cells, or otherwise pathologic cells, or activated cells, such as lymphocytes or other cells of the immune system, or activated or inflamed tissue cells comprising topically administering to the cancer tissue or surrounding tissue an effective amount of a phthalocyanine composition.06-18-2009
20100029587CYCLIC SILOXANES AND THEIR USE - The invention relates to cyclic siloxanes in which organically modifying groups are bonded to the silicon atom via an oxygen atom (SiOC linkage), and to their use in the production of polyesterpolyurethane and as additive for enhancing the activity of biocides and pesticides.02-04-2010
20120165293SYNTHESIS OF PROSTANOIDS - The presently disclosed subject matter provides a method of synthesizing prostaglandins and prostaglandin analogs comprising the ring closing metathesis of compounds of Formula (I). Also provided are novel compounds of Formula (I) and Formula (II). In addition to their use as synthetic intermediates in the presently disclosed methods, compounds of Formula (II) can be used as prostaglandin and/or prostaglandin analog prodrugs.06-28-2012
20090209490DISINFECTANT COMPOSITION - Disinfectant composition comprising slightly acidic electrolyzed water and 0.001-1.0 wt % of a polyether-modified silicone of formula (1) or formula (2)08-20-2009
20090306016FATTY ACID AMIDE HYDROLASE INHIBITORS - Disclosed are compounds of formula R—X—Y that may be used to inhibit the action of fatty acid amide hydrolase (FAAH). Inhibition of fatty acid amide hydrolase (FAAH) will slow the normal degradation and inactivation of endogenous cannabinoid ligands by FAAH hydrolysis and allow higher levels of those endogenous cannabinergic ligands to remain present. These higher levels of endocannabinoid ligands provide increased stimulation of the cannabinoid CB1i and CB2 receptors and produce physiological effects related to the activation of the cannabinoid receptors. They will also enhance the effects of other exogenous cannabinergic ligands and allow them to produce their effects at lower concentrations as compared to systems in which fatty acid amide hydrolase (FAAH) action is hot inhibited. Thus, a compound that inhibits the inactivation of endogenous cannabinoid ligands by fatty acid amide hydrolase (FAAH) may increase the levels of endocannabinoids and, thus, enhance the activation of cannabinoid receptors. Thus, the compound may not directly modulate the cannabinoid receptors but has the effect of indirectly stimulating the cannabinoid receptors by increasing the levels of endocannabinoid ligands. It may also enhance the effects and duration of action of other exogenous cannabinergic ligands that are administered in order to elicit a cannabinergic response.12-10-2009
20090306014C-10 CARBAMATES OF TAXANES - Provided herein are C-10 taxane carbamates and pharmaceutically acceptable derivatives thereof. In certain embodiments, provided herein are compounds, compositions and methods for treating cancer and taupathy.12-10-2009
20130072456BICYCLIC TETRAHYDROPYRROLE COMPOUNDS - The present invention relates to substituted bicyclic tetrahydropyrrole compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.03-21-2013
20130072455Methods and Compositions for Treating Ectoparasite Infestation - Compositions and methods for killing ectoparasites on a subject. Compositions containing a fatty acid ester, e.g., isopropyl myristate, effective for killing ectoparasites is described. Also described are compositions containing a fatty acid ester and a siloxane (e.g., decacyclomethicone). The compositions can also contain a mectin and/or a mycin, and S-methoprene. The compositions are useful against a variety of ectoparasites that afflict humans, animals, and plants, e.g., head lice, fleas, body lice, crab lice, scabies, ticks, and plant parasites.03-21-2013
20130059818CARBOSILANE DENDRIMERS AND THE USE THEREOF AS ANTIVIRAL AGENTS - Highly branched macromolecules synthesized from a polyfunctional core, preferably silicon, or polyphenolic, with a carbosilane structure at its periphery functionalized with groups, preferably anionic, giving to the macromolecule a net negative charge. Furthermore, the invention relates to the procedures for their synthesis and their uses as antiviral agents, antibacterial and antifungal agents.03-07-2013
20110015152DIARYLMETHYL AND RELATED COMPOUNDS - This invention provides compounds of formula I:01-20-2011
20090270350Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives - This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygeπase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R10-29-2009
20120225845COMPOUNDS FOR DISEASES AND DISORDERS - The invention provides novel compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). The compounds have a substituents chosen from -L-C(═O)OH, -L-CH═CHC(═O)OH, -L-C(═O)NH09-06-2012
20120225844BICYCLIC TRIAZOLE AND PYRAZOLE LACTAMS AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - In one aspect, the invention relates to bicyclic triazole and pyrazole lactams, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.09-06-2012
20130065855FUNGICIDE N-[(TRISUBSTITUTEDSILYL)METHYL]-CARBOXAMIDE DERIVATIVES - The present invention relates to fungicidal N-[(trisubstitutedsilyl)methyl]carboxamide or its thiocarboxamide derivative, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.03-14-2013
20130065854PLANT DISEASE CONTROL COMPOSITION AND ITS USE - A composition comprising a carboxamide compound represented by following formula (I), wherein R03-14-2013
20120115812SURFACE COATINGS FOR SKIN - The present invention relates to skin coating compositions and methods and, in particular, to coatings containing an active agent. In some embodiments, the coating may be applied to a skin surface and may be essentially colorless and transparent. In some aspects, the coating comprises a polymer and an active agent, and the polymer may be configured for sustained release of the active agent. In some aspects, the coating forms a barrier essentially impermeable to microorganisms yet permeable to water vapor. The coating may also be flexible and conformable to the surface. The coating may be applied to the skin using any suitable method. In some embodiments, the polymer and/or active agent are dissolved and/or suspended in a volatile solvent. In some embodiments, the volatile solvent may function as an antiseptic on skin.05-10-2012
20090048212COSMETIC COMPOSITION COMPRISING AN OIL - Cosmetic composition comprising an oil The present invention relates to a composition for making up or caring for the skin in the form of a water-in-oil emulsion comprising an aqueous phase, at least 5% by weight, relative to the total weight of the composition, of a dispersed solid phase and a liquid fatty phase having at least one non-volatile fraction, the said liquid fatty phase comprising at least one first oil chosen from slow volatile oils with an evaporation rate of between 0.002 and 0.05 mg/cm02-19-2009
20120238526ACONITINE COMPOUNDS, COMPOSITIONS, USES, AND PREPARATION THEREOF - Compound derivatives of aconitine are provided, in particular derivatives that modulate the activity of sodium channels. Also provided are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier. The subject compounds are useful in treatments, including treatments to modulate neuronal activity or to bring about muscular relaxation. The compounds also find use in the treatment of subjects suffering from a voltage-gated sodium channel-enhanced ailment or from pain. Further methods are provided for the preparation of the aconitine derivatives.09-20-2012
20080293674Azinyl Imidazoazine and Azinyl Carboxamide - The invention relates to azinylimidazoazines of structure (I) and their salts and N-oxides,11-27-2008
20120270838SPIROIMIDAZOLONE DERIVATIVE - The present invention relates to a compound represented by the following formula (1):10-25-2012
20130165408PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILESY - A method for treatment or prevention epilepsy comprising administering a phenyl carbamate compound in a pharmaceutically effective amount to a subject in need of treatment or prevention of epilepsy is provided.06-27-2013
20090042835COMPOSITIONS AND METHODS FOR AMELIORATING HYPERLIPIDEMIA - The invention provides compositions comprising a pharmaceutical compound having one or more Microsomal Triglyceride Transfer Protein (MTP) inhibitors that are covalently linked to one or more Liver Fatty Acid-Binding Protein (L-FABP) inhibitors. Also disclosed are methods for using the inventive pharmaceutical compositions in the treatment of hepatic steatosis and hyperlipidemia while avoiding the harmful side effects of steatorrhea.02-12-2009
201100772204-OXO,1-4-DIHYDROQUINOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS - The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.03-31-2011
20090124576Triazine Derivatives - Disclosed are triazine derivatives of formula05-14-2009
20100267667TELOMERASE ACTIVATING COMPOUNDS AND METHODS OF USE THEREOF - The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.10-21-2010
20100267666Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I,10-21-2010
20100240609PHTHALOCYANINE SALT FORMULATIONS - Pharmaceutical compositions of phthalocyanine compounds with a structure according to Formula (I) are described. Phthalocyanines are photosensitizer compounds having a phthalocyanine ring system that can be used for photodynamic therapy. Different phthalocyanines and phthalocyanine salts are shown to have useful characteristics such as water solubility, oil solubility, or tunable photostability. Formulations of phthalocyanines and phthalocyanine salts that can be used for topical and systemic administration are described.09-23-2010
20110144056PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH - The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease06-16-2011
20100267670NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) - The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.10-21-2010
20090203645Broad Spectrum Disinfecting and Sterilizing Composition - The present invention relates to antimicrobial compositions including an aromatic dialdehyde and a quaternary ammonium compound wherein the aromatic dialdehyde is orthophthalaldehyde, isophthalaldehyde, terephthalaldehyde, or combinations thereof, and the ratio of aromatic dialdehyde to quaternary ammonium compound is from about 10:1 to about 1:5. The invention also relates to methods of treating surfaces using the antimicrobial compositions of the invention.08-13-2009
20110301123Fungicidal Heterocyclic Amines - Disclosed are compounds of Formula 1, N-oxides, and salts thereof,12-08-2011
20110301122HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS - The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.12-08-2011
20110288050PROTEIN PHOSPHATASE INHIBITOR - Provided is a novel protein phosphatase inhibitor. The protein phosphatase inhibitor contains, as an active ingredient, a silicon compound represented by the following general formula (1) or a salt thereof, wherein R11-24-2011
20110288051TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS - Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I:11-24-2011
20110009365DERIVATIVES OF INDOLE-2-CARBOXAMIDES AND OF AZAINDOLE-2-CARBOXAMIDES SUBSTITUTED WITH A SILANYL GROUP, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - This disclosure relates to compounds of formula (I):01-13-2011
20110294756GAMMA SECRETASE MODULATORS - In its many embodiments, the present invention provides a novel class of heterocyclic compounds of Group A or Group, as defined herein, as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.12-01-2011
2010029218417BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE - The 17β-cyano-19-androst-4-ene derivatives of the present invention possess gestagenic activity. They have the general chemical formula 1, in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO11-18-2010
20100267669HETEROCYCLIC CETP INHIBITORS - Compounds of formula Ia and Ib10-21-2010
20120264713USE OF DOCOSATRIENES, RESOLVINS, AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA - The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.10-18-2012
20090203644Compositions for treating and/or preventing diseases characterized by the presence of metal ions - The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including silicon-amino compounds. In some cases, a silicon-amino compound of the invention may be bidentate, tridentate, or otherwise polydentate, and in certain instances, the silicon-amino compound, or a portion thereof, may sequester aluminum or other ions, for example, by electrostatically binding the ions. Further aspects of the invention relate to methods of making and using such compositions of the invention, as well as articles and kits associated with the compositions.08-13-2009
20090215723Organic silicic acids complex for therapeutic and cosmetic applications - This invention describes materials containing organic silica, used in cosmetic for external uses (gel, cream or lotion) or for internal uses (microbeads/beads, tablets or solutions). These materials are vegetable extracts such as bamboo or algae which constitute richest sources in organic silica (more soluble and assimilable). After extraction in a basic medium, the organic silica extract can form a stable complex at acidic pH in presence of stabilizers such as gelatin, collagen, polyethylene glycol and/or chitosan, etc. These complexes can be used for cosmetic applications in gel, lotion and cream or as a matrix in order to immobilize various bioactive molecules. For internal uses, the soluble form of monomeric or oligomeric silicic acid is necessary to preserve its assimilability. In this context, the addition of stabilizers (gelatin and/or collagen) or the functionalization of silicic acid is possible to improve its solubility and biodisponibility.08-27-2009
201002676684-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2 - The present invention comprises compounds of Formula (I).10-21-2010
20090149426PROCESS FOR SYNTHESIZING SILVER-SILICA PARTICLES AND APPLICATIONS - Size-controlled immobilization of metal nano-clusters onto particles or nanoparticles is achieved using a polyol process. Polyol processing makes it possible to use thiol groups as a chemical protocol to functionalize the surface of particles, such as silica and polystyrene nanoparticles. Metal nano-clusters, such as silver, gold, platinum and palladium, nucleate and grow on the surface of the particles. The metal nano-clusters may be synthesized in a one-pot process from metal salts, nitrates, nitrites, sulfates, sulfites and the like. Any source of metal ions compatible with the polyol suspension and selected particles may be used. The size of immobilized metal nano-clusters may be controlled by additions of a poly(vinylpyrrolidone) or other polymer capable of regulating the metal ion reduction and nucleation process and by controlling concentration of metal ions, the nucleation and/or growth temperatures, and processing time.06-11-2009
20100120714SUBSTITUTED BENZENE FUNGICIDES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof,05-13-2010
20110172185THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA - An object is to provide a novel therapeutic drug for adult T-cell leukemia having an ATL cell specific antitumor effect. The therapeutic drug for adult T-cell leukemia according to the invention is characterized by containing a compound represented by the formula I or a prodrug thereof,07-14-2011
20120035131PYRAZOLINE COMPOUNDS - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I:02-09-2012
20090306015PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS - Novel compositions of silicon-containing sulfhydryl compounds, their preparation and use in methods for treating disease are described. Silicon confers lipophilicity that can enhance the penetration of the silicon derivative sulfhydryl compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics. The organosilyl group provides compounds having improved pharmacokinetics. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.12-10-2009
20120065164FUNGICIDE PYRAZOLE CARBOXAMIDES DERIVATES - The present invention relates to pyrazole carboxamides derivatives of formula (1) wherein Y represents CR03-15-2012
20090291915Silicon Compounds and Their Use - A compound of any of formulae (I) to (III) wherein at least one of Y and Z includes a Si atom, is of utility in therapy.11-26-2009
20100087395COSMETIC PREPARATION - A cosmetic, wherein the cosmetic comprises tetraquistrimethylsiloxysilane represented by the formula (1)04-08-2010
20090088406N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS - The present invention provides a pyrrolidine compound of General Formula (1)04-02-2009
20090143333SILICONE GEL-BASED COMPOSITIONS FOR WOUND HEALING AND SCAR REDUCTION - This invention is a composition comprising a cyclic siloxane, a silicone occlusive fluid, a silicone occlusive gel, and a silicone resin powder. The composition is useful for wound healing.06-04-2009
20110172183METHOD OF FIXING ANTIBACTERIAL AGENT ARTICLE OBTAINED BY THE METHOD - An object of the present invention is to provide a method of fixing an antibacterial agent, by which method it is possible to impart articles of a wide range of materials with excellent antibacterial property and good persistence of antibacterial activity. Specifically, the method of fixing an antibacterial agent, comprises the steps of: 07-14-2011
20110172184ANTITUMOR AGENT CONTAINING 4 - [[3,5 - BIS (TRIMETHYLSILYL) BENZOYL] AMINO] BENZOIC ACID - Disclosed is a novel combination therapy of sorafenib having a remarkable antitumor effect. Specifically disclosed is an antitumor agent obtained by combining sorafenib or a salt thereof with 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid or a salt thereof.07-14-2011
20090291916Trihydroxy Polyunsaturated Eicosanoid - The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer.11-26-2009
20110269713BRYOSTATIN ANALOGUES AND METHODS OF MAKING AND USING THEREOF - Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compounds described herein can also treat memory loss. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in fewer steps and with a higher degree of substitution and specificity.11-03-2011
20110269714Polycyclic Tetracycline Compounds - The present invention is directed to a compound represented by Structural Formula (I):11-03-2011
20110207698HETEROARYL-SUBSTITUTED DICYANOPYRIDINES AND THEIR USE - The present application relates to novel heteroaryl-substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.08-25-2011
20090170811Composition for treatment of a detached retina and method of prodution thereof - The present invention relates to a composition for use in the treatment of a detached retina, comprising an oil and an additive capable of increasing the extensional viscosity of the oil. The present invention also relates to a method and kit of parts for producing the composition.07-02-2009
20090069270Methods for Diluting Water-Stabilized Antimicrobial Organosilane Compositions - The present invention relates to methods for diluting water-stable organosilane compositions comprising an organosilane, optionally having a non-hydrolyzable organic group, but having one or more hydrolyzable groups, and an acidified stabilizing solution prepared from at least one acid, and at least one cationic surfactant, preferably at least one quaternary ammonium salt (QAS), in water. The organosilane composition is diluted with a glycol ether. The resultant diluted organosilane composition may be used to antimicrobially treat a substrate.03-12-2009
20080269169Camptothecin analogs and methods of preparation thereof - A method of administering a topoisomerase inhibiting agent to a mammal includes administering a pharmaceutically effective amount of a compound having the following formula or a pharmaceutically acceptable salt thereof:10-30-2008
20080280855Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles - The invention relates to a process for the synthesis of compounds of the formula 1-a and compounds of the formula 1-b.11-13-2008
20110207699Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.08-25-2011
20080312186KETONES AND REDUCED KETONES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS - The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae and pharmaceutically acceptable salts, amides, esters, and ethers thereof, wherein: Ar1, R12-18-2008
20080312184Composition for Preventing Plant Diseases and Method for Preventing the Diseases - The present invention is to provide a composition for preventing plant diseases which comprises at least Component I and Component II, is capable of obtaining a synergic effect that cannot be expected with each single component, is capable of markedly increasing a control effect in a much smaller amount of chemicals against various plant pathogens, and causes no phytotoxicity suffering.12-18-2008
20080312183Dutpase Inhibitors - Deoxyuridine derivatives of the formula (I) where R12-18-2008
20130217650SUBSTITUTED 3-(5-MEMBERED UNSATURATED HETEROCYCLYL-1, 3-DIHYDRO-INDOL-2-ONE'S AND DERIVATIVES THEREOF AS KINASE INHIBITORS - The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.08-22-2013
20080318899Pyridazine Compounds, Compositions and Methods - The invention relates to novel chemical compounds and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.12-25-2008
20080275002Method for Treatment of Hepatic Cancer - A method for therapeutic treatment of hepatic cancer, which comprises the step of administering 10 to 30 mg per day of 4-[3,5-bis(trimethylsilyl)benzamido]-benzoic acid or a physiologically acceptable salt thereof to a patient with hepatic cancer.11-06-2008
20100137245Heteerocyclyl-substituted thiazoles as crop protection agents - Heterocyclyl-substituted thiazoles of the formula (I),06-03-2010
20100137243Oxazolidinone And/Or Isoxazoline As Antibacterial Agents - Compounds of Formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, and compounds as shown in Formula (I) wherein C is for example (D), (E), (F); wherein A and B are independently selected from (i) and (ii); R06-03-2010
20110207700TRICYCLIC COMPOUND AND USE THEREOF - The present invention relates to the compound represented by formula (I):08-25-2011
20090181928ORGANIC COMPOUNDS - Compounds of the formula07-16-2009
20090118232INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, 1,2-BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF - The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.05-07-2009
20090325902HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF - Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.12-31-2009
20090325901IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS - The present invention relates to compounds of formula I or II: —wherein R is an alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, or aralkynyl group, that may be substituted or unsubstituted, and that optionally includes at least one heteroatom in its carbon skeleton; R12-31-2009
20100004201Cosmetic - The present invention provides a cosmetic that contains glycerin modified on both ends with silicone represented by the following general formula (a).01-07-2010
20110144058INSECTICIDAL COMPOSITIONS - The present invention relates to insecticidal mixtures of chloronicotinyl insecticides of the formula (I)06-16-2011
20090062234SUBSTITUTED ORGANOPOLYSILOXANES AND USE THEREOF - The invention relates to new compounds of Formula (1): wherein Q is selected from CXYR′ and RC(Z) wherein Z is selected from oxygen, hydrogen, OH, NR03-05-2009
20090197833Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same - Silicon-containing compounds having selective COX-2 inhibitory activity, as well as compositions thereof are provided. The subject compounds find use in a variety of applications, including therapeutic applications. Also provided are kits containing the subject compounds and pharmaceutical preparations thereof.08-06-2009
20090181929ORGANIC COMPOUNDS - The present invention provides a compound of formula (I):07-16-2009
200802619202-Aminooxazolines as TAAR1 ligands - The invention relates to compounds of formula I10-23-2008
20080261918Silicon Compounds and Their Use - A compound of any of formulas (I) to (V): wherein at least one of Y and Z includes a Si atom, is of utility in therapy.10-23-2008
20080261917Isoindolin-1-One Derivatives - A compound of formula10-23-2008
20080261919Camptothecin-analog with a novel, "flipped" lactone-stable, E-ring and methods for making and using same - The present invention discloses: (i) a novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (ii) methods of synthesis of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof; (iii) pharmaceutically-acceptable formulations comprising said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents; (iv) methods of administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more additional chemotherapeutic agents, to subjects in need thereof; and (v) devices for the administration of said novel, lactone-stable, “flipped” E-ring camptothecin, pharmaceutically-acceptable salts, and/or analogs thereof, and, optionally, one or more chemotherapeutic agents, to subjects in need thereof.10-23-2008
20120077776HYDROLYSIS RESISTANT ORGANOMODIFIED TRISILOXANE SURFACTANTS - Three types of trisiloxane surfactants having the basic formula:03-29-2012
20110144057ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF - The present invention is directed to compounds of formula (I)06-16-2011
20120196832SUBSTITUTED POLYALKOXYSILOXANE COMPOSITIONS AND METHODS OF USE - Linear polydialkoxysiloxanes with 2-8 polymeric units have been reacted with alcohols by a transetherification reaction to provide hydrophilic and water soluble silicone products. The glycerol substituted siloxanes in particular are effective in topically treating skin lesions such as radiation burns. Compositions including the substituted polydialkoxysiloxane products inhibit biofilm formation when used as coatings on hard surfaces.08-02-2012
20100160255SPIRO-CYCLIC COMPOUND - The present invention provides a compound represented by the formula (I):06-24-2010
20100261673ANTIBACTERIAL COMPOUNDS AND METHODS OF USING SAME - Embodiments of the present invention provide novel antibacterials that target penicillin-binding proteins or other important cellular targets. Methods for inhibiting growth (reproduction, etc.) of bacteria using compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, such as certain strains of 10-14-2010
20090082308Benzothiophene derivatives - The present invention relates to a novel class of benzothiophene amide derivatives. The hydroxamic acid compounds can be used to treat cancer. The benzothiophene amide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.03-26-2009
20110059920AGENT FOR REGENERATION AND/OR PROTECTION OF NERVES - An EP2 agonist which may have an EP3 agonistic effect has an effect of regenerating and/or protecting nerves, and is therefore useful as a therapeutic agent for a disease of the peripheral nervous system, such as a lower or upper motor neuron disease, a nerve root disease, plexopathy, thoracic outlet compression syndrome, peripheral neuropathy, neurofibromatosis and neuromuscular transmission disease. An EP2 agonist which has an EP3 agonistic effect is a safe and effective agent for the regeneration and/or protection of nerves which has little influence on the circulatory system.03-10-2011
20110130361SILICON DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS - The present invention relates to a novel class of Silicon derivatives. The Silicon compounds can be used to treat cancer. The Silicon compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the Silicon derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the Silicon derivatives in vivo.06-02-2011
20100240610QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF - This invention relates to new quinolone based compounds that exhibit prolyl hydroxylase inhibitory activity. This invention also relates to methods of increasing HIF levels or activity in a subject or treating a condition associated with HIF levels or activity in a subject by administering to the subject at least one quinolone based compound. This invention further involves assays for the detection of a hydroxyproline residue in a HIF molecule.09-23-2010
20100234323Antimicrobial Acids and Salts - The invention relates to novel acidic siloxane derivatives, the use, methods of use or processes making use of siloxane derivatives of this type, especially to achieve an anti-microbial, preservative and/or antiadhesive effect, for the protection of articles and/or materials, and a process for the manufacture of the novel compounds. The siloxane acids (which may also be in salt form) have the formula (I), formula (II) and/or formula (III), wherein the symbols have the meanings given in the specification.09-16-2010
20100216744THICKENER/GELLANT FOR OILY SUBSTANCE - The purpose of the invention is to provide a thickening and gelling agent that is easily dispersed into an oily substance such as a silicone oil in a small addition amount, is free of liquid separation, stably forms a thickened material or a gel state, and can prepare a thickened product or a gel having spreadability and free of sticky feeling and dry feeling. The invention provides a thickening and gelling agent for an oily substance containing the components (A) a modified product of alkoxytitanium or alkoxyzirconium with a carboxylic acid and a hydroxy compound, and (B) at least one silicone oil selected from a silicone oil having an amino group and a silicone oil having a carboxyl group; an oily composition and a cosmetic preparation, containing the thickening and gelling agent.08-26-2010
20100144671Compositions and Methods for Cancer Treatment - Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.06-10-2010
20100210590COMPOSITIONS AND TREATMENTS FOR SEIZURE-RELATED DISORDERS - The present invention relates to therapeutic and/or prophylactic uses of pyridazine compounds and to pharmaceutical compositions containing one or more of these compounds as an active component for treating a disorder characterized by conduction disturbances, electroconvulsions and/or seizures, in particular epilepsy, more particularly pediatric epilepsy. In an aspect of the invention, the pyridnsine compound has the Formula (Ia) or (Ib) wherein R08-19-2010
20120142633METHYLPYRROLOPYRIDINECARBOXAMIDES - The compounds of Formula (I),06-07-2012
20110130362A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A06-02-2011
20100197633 N-Alkyl-Heterocyclyl Carboxamide Derivatives - A compound of general formula (I):08-05-2010
20090318385Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient - A novel pyrazolopyridine derivative is provided which is useful as a pharmaceutical drug having phosphodiesterase inhibitory activity.12-24-2009
20080312185SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES - Disclosed are methods of treating cancer by administration of compounds according to formula (I):12-18-2008
20100222300A2B Adenosine Receptor Antagonists - Disclosed are novel compounds that are A09-02-2010
20130131015SYNTHESIS AND REGIOSELECTIVE SUBSTITUTION OF 6-HALO- AND 6-ALKOXY NICOTINE DERIVATIVES - The present invention provides active compounds for modulating nicotinic acetylcholine receptors and methods of making the same. The methods of preparing the active compounds utilize different intermediate compounds.05-23-2013
20100305066Fused Thiophene Derivatives as Kinase Inhibitors - A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.12-02-2010
20100323987COMBINATIONS OF RETIGABINE AND SODIUM CHANNEL INHIBITORS OR SODIUM CHANNEL-INFLUENCING ACTIVE COMPOUNDS FOR TREATING PAINS - The invention relates to pharmaceutical combinations of retigabine and sodium channel inhibitors for treating, pains which are accompanied by an increase in muscle tone.12-23-2010
20120270839COMPOSITIONS AND METHODS FOR CANCER TREATMENT - Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.10-25-2012
20110009364AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The disclosure relates to compounds of formula (I):01-13-2011
20110021460SELECTIVE HYDROSILYLATION METHOD AND PRODUCT - An asymmetric siloxane is made by reacting a silicone having the formula M01-27-2011
20110021459DUTPASE INHIBITORS - Deoxyuridine derivatives of the formula01-27-2011
20110034414FLUOROALKYLOXY ALKANES, PROCESS FOR PRODUCTION AND USES THEREOF - The present invention relates to fluoroalkyloxy alkanes having formula (I): R02-10-2011
201002860883-Substituted-4-Oxo-3,4-Dihydro-Imidazo[5,1-d][1,2,3,5-Tetrazine-8-Carboxy- lic Acid Amides and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (collectively referred to herein as 3TM compounds). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit cell proliferation, and in the treatment of proliferative disorders such as cancer, etc., and methods of preparing such compounds.11-11-2010
20110082107INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 - The present invention relates to compounds with the formula (I), (II), (III) or (IV):04-07-2011
20100222299COMPOUND - The present invention involves tetrahydroisoquinoline compounds and their use in the inhibition and/or prevention of tumor growth.09-02-2010
20100210592AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS - The invention relates to the use of compounds of formula I08-19-2010
20120245124TRPV3 Modulators - Disclosed herein are modulators of TRPV3 of formula (I)09-27-2012
20100004202Quaternary ammonium-functionalized-POSS compounds - A silsesquioxane cage structure has a general formula [R01-07-2010
20120245125PYRIDAZINE COMPOUNDS, COMPOSITIONS AND METHODS - The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of making and using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for, research, drug screening, and therapeutic applications.09-27-2012
20100056477FUNGICIDAL MIXTURES OF AMIDINYLPHENYL COMPOUNDS - This invention relates to fungicidal mixtures of certain phenylamidines, their N-oxides, and/or agriculturally suitable salts thereof, and to compositions comprising such mixtures and methods for using such mixtures as fungicides.03-04-2010
20090215724Pyrrolopyrazine kinase inhibitors - The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I,08-27-2009
20090215725Substituted 4-aminocyclohexane derivatives - Substituted 4-aminocyclohexane derivatives having the formula I:08-27-2009
20110086817ANTI-BACTERIAL AGENTS FROM BENZO[D]HETEROCYCLIC SCAFFOLDS FOR PREVENTION AND TREATMENT OF MULTIDRUG RESISTANT BACTERIA - Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria.04-14-2011
20100069328NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER - The present invention is directed to a compound of formula I,03-18-2010
20110086816Antimicrobial Compounds - The invention relates to cationic siloxane derivatives for use especially as fungicides and/or antiadhesives. The cationic siloxane derivatives have the formula (I), wherein R1, R2, R3, R4, R04-14-2011
20110009363SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES) - This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-γ, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.01-13-2011
20130165410PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING STROKE - A phenyl carbamate compound; a composition for treating and/or preventing stroke containing the phenyl carbamate compound or a pharmaceutically acceptable salt thereof as an active ingredient; a method of treating and/or preventing stroke comprising administering the phenyl carbamate compound or a pharmaceutically acceptable salt thereof to a patient in need of stroke treatment; and a use of the phenyl carbamate compound or a pharmaceutically acceptable salt thereof in treating and/or preventing stroke, are provided.06-27-2013
20130165409PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN - A phenyl carbamate compound; a composition for treating and/or alleviating pain containing the phenyl carbamate compound or a pharmaceutically acceptable salt thereof as an active ingredient; a method of treating and/or alleviating pain comprising administering the phenyl carbamate compound or a pharmaceutically acceptable salt thereof to a patient in need of pain treatment; and a use of the phenyl carbamate compound or a pharmaceutically acceptable salt thereof in treating and/or alleviating pain, are provided.06-27-2013
20100004203MEDICAMENT FOR PREVENTIVE AND/OR THERAPEUTIC TREATMENT OF BOWEL DISEASE - A medicament for preventive and/or therapeutic treatment of a bowel diseases such as inflammatory bowel diseases including Crohn's disease, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.01-07-2010
20120202774ACYLOXY- AND PHOSPHORYLOXY-BUTADIENE-FE(CO)3 COMPLEXES AS ENZYME-TRIGGERED CO-RELEASING MOLECULES - The present invention provides acyloxy- and phosphoryloxy-butadiene-Fe(CO)08-09-2012
20090137527Compositions and methods for modulating immune function - The invention relates to methods of modulating immune function, suppressing immune response, treating autoimmune diseases or autoimmune disorders, and treating diseases, sequelae or pathological conditions mediated by an activation of the immune system comprising administering a compound of formula A, a compound of any one of formulae 1-49, a lipoxin compound, or an oxylipin compound.05-28-2009
20080318900Cosmetic Compositions Comprising At Least One Bis-Urea Derivative - Disclosed herein is a cosmetic composition comprising at least one continuous liquid fatty phase, comprising at least one compound of formula (I), or a salt and/or isomer thereof:12-25-2008
201100538915-FLUOROPYRIMIDINONE DERIVATIVES - This present disclosure is related to the field of 5-fluoropyrimidinones and their derivatives and to the use of these compounds as fungicides.03-03-2011
20100227837Mobile Self-Spreading Biocides - A compound having the formula:09-09-2010
20110028433QUINAZOLINONE DERIVATIVES AS TUBULIN POLYMERIZATION INHIBITORS - The present invention provides compounds of formula (I), their use as inhibitors of tubulin polymerization as well as pharmaceutical compositions comprising said compounds of formula (I)02-03-2011
201102571282-Alkyl-Cycloalk(en)yl-Carboxamides - Novel 2-alkylcycloalk(en)ylcarboxamides of the formula (I)10-20-2011
20110257127A2B ADENOSINE RECEPTOR ANTAGONISTS - Disclosed are novel compounds that are A10-20-2011
20100298267AMINOPYRIMIDINAMIDES AS PESTICIDES - The present application relates to novel aminopyrimidinamides, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.11-25-2010
20110136762FUNGICIDAL PYRIDAZINES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof,06-09-2011
20110136761Vapour of a Citrus Essential Oil Blend and Its Antimicrobial Properties - A vapour of a blend comprising the oil of orange and the oil of bergamot, a process for its preparation and its use as an antimicrobial. The vapour has been found to be particularly useful on food contaminated with microorganisms without affecting the sensory properties of the food.06-09-2011
20120065162N-N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS - The present invention provides a pyrrolidine compound of General Formula (1)03-15-2012
20100179105KERATIN MATERIALS MAKE-UP KIT COMPRISING REACTIVE SILICONE COMPOUNDS AND A COMPATIBLE OIL - The invention provides a make-up kit comprising at least two compositions which are packaged separately, —the kit comprising at least one compound X, at least one compound Y and at least one catalyst or one peroxide, at least one of the compounds, X or Y, being a silicone compound, —with the proviso that the compounds X and Y—and the catalyst are not simultaneously in one of said compositions, —said compounds X and Y being able to react together by a hydrosilylation reaction or by a condensation reaction, when they are brought into contact with one another, —one at least of the first and second compositions comprising at least one compatible oil, —said compounds X and Y and said compatible oil, and their respective amounts, being such that the transfer index of a deposit comprising the two compositions is less than or equal to 40 out of 100. Finally, the invention relates to a method of making-up keratin materials that involves applying the compounds X and Y and the compatible oil.07-15-2010
201203025241,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND - Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R11-29-2012
20120302523ENDOPEROXIDES AND METHODS OF PHOTOCATALYTICALLY SYNTHESIZING ENDOPEROXIDES - A method of making an endoperoxide from a diene and oxygen in the presence of a photocatalyst having an excited state lifetime of at least 100 nanoseconds, the endoperoxide being represented by the formula:11-29-2012
20120309715Use of Simethicone in Constipated Patients - Methods of treatment and kits using simethicone and another medicament, in a combined form, or separately or separately and sequentially wherein the sequential administration is close in time, as a medication for the treatment of constipated persons suffering from bloated feeling and gas discomfort during the night.12-06-2012
20120309714Heteroaromatic Phenylimidazole derivatives as PDE10A enzyme inhibitors - This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.12-06-2012
20120309713N-Cyclopropyl-(20R)-2-Methylene-19,26,27-Trinor-25-Aza-Vitamin D Analogs and Their Uses - This invention discloses N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-vitamin D analogs, and specifically N-cyclopropyl-(20R)-2-methylene-19,26,27-trinor-25-aza-1α-hydroxyvitamin D12-06-2012
20090176738Dermal medicament delivery system - There is provided a means of applying a heated medicament to the skin and concurrently hydrating the skin thus raising the efficacy of administration.07-09-2009
20100190745HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF - Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.07-29-2010
20100190746QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS - Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.07-29-2010
20110263529GAMMA SECRETASE MODULATORS - In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions.10-27-2011
201000295894,5-DIHYDRO-OXAZOL-2YL DERIVATIVES - The invention relates to compounds of formula I02-04-2010
20100029588SUBSTITUTED PHENYLAMIDINES AND THE USE THEREOF AS FUNGICIDES - The present invention relates to oxime ether-, hydrazone- or azomethine-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the amidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.02-04-2010
20100022475NOVEL TRIAZOLOPYRIMIDINE DERIVATIVES - The present invention relates to novel triazolopyrimidine derivatives of formula I as active ingredients which have microbiocidal activity, in particular fungicidal activity(I): wherein the substituents are as defined in claim 01-28-2010
20120232033AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS - The invention relates to the use of compounds of formula I09-13-2012
20120172334CONTROLLED RELEASE PARTICLES AND METHOD FOR PRODUCING THE SAME - Controlled release particles are obtained by dissolving a hydrophobic antibiotic compound in a hydrophobic polymerizable vinyl monomer without the presence of a solvent, thereby preparing a hydrophobic solution, the hydrophobic antibiotic compound having a melting point of 100° C. or less, a polar term δp,compound of 2 to 8 [(J/cm07-05-2012
20110136760Kinase Inhibitors Useful for the Treatment of Myleoproliferative Diseases and other Proliferative Diseases - The present invention is concerned with novel compounds useful in the treatment of hyperproliferative diseases and mammalian cancers, especially human cancers. The invention also pertains to methods of modulating kinase activities, pharmaceutical compositions, and methods of treating individuals, incorporating or using the compounds. The preferred compounds are active small molecules set forth in formulae Ia-Iww.06-09-2011
20130012476COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention relates to compounds of formula (I)01-10-2013
20110306576COMPOUNDS AND METHODS RELATING THERETO - A compound of formula (II) or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen; wherein X is selected from O, S and Se; each of R12-15-2011
20120040930TETRACYCLIC TERPENE SERIES COMPOUNDS, METHODS FOR PREPARING SAME, USES THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOUNDS CONTAINING SAME - The invention concerns a triterpene alkaloid of general formula (I). The invention also concerns a method for making same and use thereof as medicine.02-16-2012
20100184724COMPOSITIONS FOR TREATING AND/OR PREVENTING DISEASES CHARACTERIZED BY THE PRESENCE OF METAL IONS - The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including organosilicon compounds. A composition of the invention may be administered to a mammal, such as a human. In some cases, the composition may include a silanol, a silandiol, a silantriol, or a cyclic organosilane, and/or be able to form a silanol, a silandiol, or a silantriol upon exposure to physiological conditions such as are found in the blood, in the stomach and/or gastrointestinal tract, or in the brain or other organ. In certain cases, the organosilicon compound may be bound to a moiety able to be transported across the blood-brain barrier into the brain, for example, an amino acid, a peptide, a protein, a virus, etc. The organosilicon compound may also be labeled (e.g., fluorescently or radioactively) in certain instances. In some embodiments, the composition, or a portion thereof, may sequester aluminum, copper, iron or other ions, for example, by electrostatically binding to the ions. The composition may also include other functionalities such as amines, certain alkyl and/or aryl moieties (including substituted alkyls and/or aryls), or hydrophobic moieties, for example, to facilitate transport of the organosilicon compound through the blood-brain barrier.07-22-2010
20120040931NOVEL ORGANOPOLYSILOXANE AND COSMETIC CONTAINING THE SAME - There is disclosed an organopolysiloxane represented by the following general formula (1).02-16-2012
20120065163SEBUM ABSORPTION COMPOSITIONS - Sebum absorption compositions are disclosed which include (a) 1% to 20% by weight of the composition of a sebum absorption ingredient; and (b) 20% to 99% by weight of the composition of a volatile solvent.03-15-2012
20100190747Fused ring compound and use thereof - The present invention provides a compound represented by the formula:07-29-2010
20110319359INDANYL COMPOUNDS - Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof:12-29-2011
20120046242MOLECULAR ACTIVATORS OF THE WNT/BETA-CATENIN PATHWAY - The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.02-23-2012
20120004196Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.01-05-2012
20120010168Unique Dual-Action Therapeutics - A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X═C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.01-12-2012
20120010169Solubilized Composition - This invention provides a solubilized composition in which a carboxy-modified silicone is solubilized in a large amount and stably. The solubilized composition is characterized by consisting of (a) one or more nonionic surfactant(s), having a weighted average of the HLB value of 10 to 15, selected from polyoxyethylene alkyl ether type nonionic surfactant represented by the following formula (I) or (II):01-12-2012
20100113391BICYCLIC HETEROCYCLIC COMPOUND05-06-2010
20110166102NOVEL 2-SUBSTITUTED BENZIMIDAZOLES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) - The present invention is directed to a novel 2-substituted benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.07-07-2011
20120015905COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.01-19-2012
20120058973COMPOSITIONS COMPRISING A SILICONE WATER-IN-OIL EMULSIFIER AND A LOW NITROGEN CONTAINING AMINO-FUNCTIONAL SILICONE GUM - Provided are compositions comprising a silicone water-in-oil emulsifier, a low nitrogen containing amino-functional silicone gum, a hydrophobic agent, a non-silicone primary emulsifier, and water.03-08-2012
20120157410COMPOSITIONS AND TREATMENTS USING PYRIDAZINE COMPOUNDS AND CHOLINESTERASE INHIBITORS - The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.06-21-2012
20120108545Trioxane Monomers and Dimers - Monomeric and dimeric trioxane fluoroaryl amides, 5-carbon-linked, C-10 non-acetal trioxane dimer esters; trioxane silylamides; and trioxane dimer orthoesters and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.05-03-2012
20120071444METHOD AND COMPOSITION FOR THE CONTROL OF ECTOPARASITES - An ectoparasiticidal composition is provided that comprises a mixture of a carrier and an active with an emulsifying agent. The carrier comprises non-volatile low viscosity siloxane and the active comprises a non-volatile high viscosity siloxane. The low viscosity siloxane and the high viscosity siloxane both have a closed cup flash point of at least 100° C. Preferably, both the low viscosity siloxane and the high viscosity siloxane comprise a dimeticone or a dimeticonol or a mixture of same, the the low viscosity siloxane having a viscosity in the range of 5 to 1000 centistokes inclusive and the high viscosity siloxane having a viscosity of at least 1000 centistokes.03-22-2012
20110092455Method and Composition for the Control of Arthropods - The present invention relates to the use of certain siloxanes and mixtures thereof in the control of arthropods such as insects and arachnids, and in particular ectoparasites, such as head lice.04-21-2011
20100137244PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS - Chemical syntheses and medical uses of novel modulators of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and diastereomeric mixtures of isomers, individual diastereomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment and/or management of hypercholesterolemia, dyslipidemia, coronary artery disease, atherosclerosis, metabolic syndrome, a hyperproliferative disease such as colorectal cancer, prostate cancer, and melanoma, a neurodegenerative disease such as cerebral ischemia, Alzheimer's disease, and Parkinson's disease are described.06-03-2010
20120252758Novel Bicyclic Pyridinones - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I10-04-2012
20110039802NPY Y5 ANTAGONIST - The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I):02-17-2011
20110065667PHENYLPYRAZOLE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases.03-17-2011
20110065669OXAZOLOBENZIMIDAZOLE DERIVATIVES - The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.03-17-2011
20110065668PHENYLPYRAZOLE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases.03-17-2011
20110105430PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS - Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (A) are inhibitors N of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.05-05-2011
20110105429Thiazole-4-Carboxylic Acid Esters and Thioesters as Plant Protection Agents - The use of thiazole-4-carboxylic esters and thioesters of the formula (I)05-05-2011
20110105428HYDROLYSIS RESISTANT ORGANOMODIFIED SILYLATED IONIC SURFACTANTS - The present invention provides for a composition comprising a silane having the formula:05-05-2011
20110105427DEAZAPURINES AND USES THEREOF - The present invention provides compounds having formula (I):05-05-2011
20100093665SILYLATED PIPERIDINE DERIVATIVES - Compounds of formula I: I wherein at least one of R4 and R5 comprises Si(R6)3 as a substituent selectively attenuate production of Aβ(1-42) and hence find use in treatment of Alzheimer's disease and related conditions.04-15-2010
20100093666WATER-STABILIZED ANTIMICROBIAL ORGANOSILANE PRODUCTS, COMPOSITIONS, AND METHODS FOR USING THE SAME - The present invention relates to water-stable compositions and compounds formed by mixing an organosilane, optionally having a non-hydrolyzable organic group, but having one or more hydrolyzable groups, and an acidified stabilizing solution prepared from at least one acid, at least one glycol ether, and at least one cationic surfactant, preferably at least one quaternary ammonium salt (QAS), in water. The present invention also relates to methods of treating a substrate by mixing or contacting the substrate with the product, compound, or composition of this invention for a period of time sufficient for treatment of the substrate, methods of antimicrobially treating a food article, methods of antimicrobially coating a fluid container, methods of dyeing and treating a substrate, and methods of antimicrobially coating a latex medical article. The invention also pertains to a treated substrate having adhered thereto the product, compound, or composition of this invention.04-15-2010
20120122816COMPOSITIONS AND METHODS FOR ORGAN PRESERVATION - The invention relates to reducing, preventing or reversing organ damage, reducing and/or preventing stem cell damage and/or death, enhancing organ preservation and/or survival, or enhancing stem cell preservation and/or survival comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, an oxylipin compound, or a combination of aspirin and an omega-3 fatty acid.05-17-2012
20090131365NOVEL HETEROCYCLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) - The present invention is directed to novel heterocycle derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.05-21-2009
201101839381,7-DIAZACARBAZOLES AND METHODS OF USE - The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.07-28-2011
20110183939NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present invention provides a novel P2X07-28-2011
20110183937Agent for Combating Ectoparasites - Disclosed is a composition for killing ectoparasites and/or their eggs, comprising at least one volatile, at room temperature liquid, non-polar organic solvent, 1 to 10 wt.-%, based on the total composition, of at least one spreading agent; and 35 to 65 wt.-%, based on the total composition, of at least one polysiloxane having a viscosity of greater than 90 cSt.07-28-2011
201201652944,5-DIHYDRO-OXAZOL-2YL DERIVATIVES - The invention relates to compounds of formula I06-28-2012
20120214764METHOD AND KIT FOR GASTRO-INTESTINAL CLEANSING - A method of cleansing a mammalian GI tract is described and includes ingestion of polyethylene glycol (PEG) and magnesium citrate in a split-dose regimen. The split-dose regimen provides effective cleansing of the GI tract while minimizing discomfort and side effects to the patient A kit packaged with a first and second portion of PEG, and a first and second portion of magnesium citrate, and optionally simethicone is also provided.08-23-2012
201202147626,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR - The invention relates to novel compounds of Formula I:08-23-2012
20120135958TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to compounds of formula (I), where: A is a bond, an oxygen, or an 05-31-2012
20120172333PYRROLO-PYRIDINE DERIVATIVES AS ACTIVATORS OF AMPK - The present invention relates to pyrrolopyridone compounds of the formula (I),07-05-2012
20120214763MEMORY FIXATION ACCELERATOR - A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid.08-23-2012
20100273739Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy - The present invention relates to aminotetraline derivatives of the formula (I)10-28-2010
20120178713PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS - The present invention relates to phenyl sulfonamides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including for example the treatment of pain.07-12-2012
20100009933HYDROXYLATED AMIDE SKIN MOISTURIZER - The invention relates to the cosmetic use, as a skin moisturizer, of a compound of formula (I): with (i) R01-14-2010
20100210591BIS(TRIMETHYLSILYL)PHENYL COMPOUND OR SALT THEREOF, AND USE THEREOF - The present invention provides a compound that exhibits an excellent antitumor effect and reduces side effects, such as skin disorders, of the existing retinoid by selectively activating on the nuclear receptor RARα, thereby possibly producing significant improvement of clinical profits. Specifically, the present invention provides a bis(trimethylsilyl)phenyl compound represented by Formula (I):08-19-2010
20120220550PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME - The present invention provides pyrazole derivative compounds and pharmaceutically acceptable salts thereof. The compounds of the present invention have an excellent effect of preventing and treating osteoporosis.08-30-2012
20120220549Pituitous Silicone Fluids - Fluid compositions are disclosed containing a branched organopolysiloxane and a carrier fluid. The branched organopolysiloxane is obtainable by reacting an organohydrogencyclosiloxane and an alkenyl terminated polydiorganosiloxane. The disclosed fluid compositions possess pituitous rheological properties.08-30-2012
20090149425Malononitrile compound as pesticides - The present invention provides a malononitrile compound represented by the formula (I): wherein any one of X06-11-2009
20090018103Diaminoalkane Aspartic Protease Inhibitors - Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.01-15-2009
20110046088IMINIPYRIDINE DERIVATIVES AND THEIR USES AS MICROBIOCIDES - Compounds of the formula (I) in which the substituents are as defined in claim 02-24-2011
20120322761HETEROCYCLIC CETP INHIBITORS - Compounds of formula Ia and Ib12-20-2012
20110224170Pyranopyranone derivatives as antimicrobial agents - Disclosed is the use of pyranopyranone derivatives of formula09-15-2011
20110237546METHOD FOR TREATING A MAMMAL BY ADMINISTRATION OF A COMPOUND HAVING THE ABILITY TO RELEASE CO - Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.09-29-2011
20110237545TRIHYDROXY POLYUNSATURATED EICOSANOID DERIVATIVES - The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer.09-29-2011
20100234324Quinazolinamide derivatives - Novel quinazolinamide derivatives of the formula (I), in which R09-16-2010
20120277186Tricyclic Derivatives and Their Pharmaceutical Use and Compositions - This application relates to tricyclic compounds of Formula I:11-01-2012
20100029586Packaging for a Fabric softening Composition - A packaged product comprising packaging in combination with a fabric softening composition incorporating a skin benefit agent as an ingredient to enable the fabric softening composition to render textile fabrics treated with the composition capable of delivering the skin benefit agent to the skin with which the fabrics come into contact, characterised in that the packaging incorporates tactile cues (02-04-2010
20120101061COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION - The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.04-26-2012
20120149662Heterocyclic Compounds as Janus Kinase Inhibitors - The invention provides compounds of formula (I):06-14-2012
20120149661TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS - The invention relates to tetra-substituted heteroarylic compounds of the formula (I)06-14-2012
20120149660NOVEL N-SUBSTITUTED 5-HYDROXYPYROLLINDES AS INHIBITORS OF MDM2-P53 INTERACTIONS - There are provided compounds of formula I06-14-2012
20130018017QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS - The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I)01-17-2013
20130018016Agent for Combating Ectoparasites - Disclosed is a composition for killing ectoparasites and/or their eggs, comprising at least one volatile, at room temperature liquid, non-polar organic solvent, 1 to 10 wt.-%, based on the total composition, of at least one spreading agent; and 35 to 65 wt.-%, based on the total composition, of at least one polysiloxane having a viscosity of greater than 90 cSt.01-17-2013
20080255068Chemical Compound and Its Use - The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias and arteriosclerosis.10-16-2008
20080255069Medicament for Preventive and/or Therapeutic Treatment of Bowel Disease - A medicament for preventive and/or therapeutic treatment of a bowel diseases such as inflammatory bowel diseases including Crohn's disease, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.10-16-2008
20130143841BENZOHETEROCYCLIC ANTI-BACTERIAL AGENTS - Embodiments herein provide compounds and methods of making and using such compounds for prevention and treatment of multidrug resistant bacteria. In particular, embodiments are directed to anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria.06-06-2013
20120252760NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES - The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.10-04-2012
20120252759THIAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER - Compounds of the formula Ia and Ib, in which R10-04-2012
20120252757ORGANOPOLYSILOXANE AND COSMETIC CONTAINING IT - The invention provides an organopolysiloxane shown by the following formula (1);10-04-2012
20110269712Fungicidal Carboxamides - This invention is directed to compounds of Formula (1) including all geometric and stereoisomers, N oxides, and agriculturally suitable salts thereof, agricultural compositions containing them and their use as fungicides, (1) provided that the compound of Formula 1 is other than 2-[1-[(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]-4-thiazolecarboxamide and R11-03-2011
20130172292FUSED HETEROCYCLIC COMPOUNDS - The present invention provides a compound which has the effect of PDE 10A inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound represented by the formula (1′): wherein, Ring A′ represents an optionally substituted pyridine ring, an optionally substituted pyridazine ring, a pyrimidine ring, or 10 a pyrazine ring, R1′ represents (1) wherein, R07-04-2013
20130137658PLANT DISEASE CONTROLLING COMPOSITION AND USE THEREOF - A plant disease controlling composition is provided containing a pyridazine compound represented by formula (I):05-30-2013
20130096083USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME - The use of isoquinolones for preparing drugs, including novel isoquinolones as well as their synthesis method. In particular, isoquinolone derivatives used in the treatment of pathological angiogenesis, and more particularly of cancer.04-18-2013
20130096084NOVEL HETEROCYCLIC COMPOUNDS AS ERK INHBITORS - The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.04-18-2013
20130102568ALKOXYIMINO DERIVATIVE AND PEST CONTROL AGENT - [PROBLEMS] The present invention provides a novel alkoxyimino derivative or a salt thereof, as well as to a pest control agent containing the derivative or salt thereof as an active ingredient, which shows an excellent pest control effect on a wide range of pests in the agricultural and horticultural field and is also capable of controlling resistant pests.04-25-2013
20130210769COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF CANNABINOID RECEPTOR 1 ACTIVITY - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).08-15-2013
201301025673-Desoxy-2-Methylene-Vitamin D Analogs and Their Uses - This invention discloses 3-desoxy-2-methylene-vitamin D analogs, and specifically (20S)-3-desoxy-1α,25-dihydroxy-2-methylene-vitamin D04-25-2013
20100069329COSMETIC COMPOSITIONS COMPRISING HYDROLYSIS RESISTANT ORGANOMODIFIED DISILOXANE SURFACTANTS - Compositions comprising disiloxane surfactant compositions comprising a silicone composition comprising a silicone having the formula:03-18-2010
20080200432Fiber-Treating Agent - The present invention relates to a fiber-treating agent having a pH value of 2 to 5 at 20° C. and containing an alkoxysilane (a), an organic acid (b) and water (c), wherein 50% or more by weight of the component (a) is an alkoxysilane represented by the following formula (1): R08-21-2008
20110275595Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use - The present invention relates to compounds defined by formula I wherein the groups R11-10-2011
20120277185Pesticidal Carboxamides - To provide novel carboxamides which exhibit an excellent pesticidal activity as pesticides. Carboxamides represented by the following Formula (I) and use thereof as pesticides and an animal parasite control agent:11-01-2012
201301503253-(Fluorovinyl)pyrazoles and their use - The present application relates to novel 3-(fluorovinyl)pyrazole derivatives, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.06-13-2013
20100286089Process for the Preparation of Entecavir and Novel Intermediates Thereof Via Carbon-Silicon Oxidation - Processes for preparing entecavir and novel intermediates thereof using carbon-silicon oxidation.11-11-2010
20100317620N-PHENYLIMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDE COMPOUNDS, PREPARATION AND THERAPEUTIC USE THEREOF - Compounds of formula (I):12-16-2010
20100317619Selective Agents for Pain Suppression - In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of the often chronic, severe and debilitating pain that can accompany inflammatory diseases and neuropathic insults, pain that is often unresponsive to conventional analgesic treatment. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of neuropathic pain, migraine-related pain and inflammatory pain with reduced sedative and ataxic side effects.12-16-2010
20110312915Novel cosmetic compositions - The present invention is concerned with novel cosmetic or pharmaceutical compositions. More particularly, the invention is concerned with novel cosmetic or pharmaceutical compositions for treating or preventing any symptoms caused by negative developments of the physiological homeostasis of healthy skin, as well as for the promotion of hair growth and protection from hair loss.12-22-2011
20130184238AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY - The present invention relates to aminotetraline derivatives of the formula (I)07-18-2013
20130184239COMBINATION OF SILOXANE AND ACTIVE INGREDIENT FOR TREATING DENTAL DISORDER - The invention relates to a pharmaceutical composition comprising a siloxane according to general formula (I)<07-18-2013
20130157976NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES - The invention relates to novel pyrido[2,3-b]pyrazine derivatives of the general formulae (I) and (II), and to their preparation and use as medicaments, especially for the treatment of malignant disorders and other disorders based on pathological cell proliferations.06-20-2013
20120283217MODULATORS OF AMYLOID-BETA PRODUCTION - As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.11-08-2012
20120283216FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES - Disclosed are compounds of Formula 1, N-oxides, and salts thereof,11-08-2012
20130190271FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF - Disclosed is a harmful arthropod control composition comprising, as an active ingredient, a fused heterocyclic compound represented by formula (1) [wherein A07-25-2013
20130190272PEST CONTROLLING COMPOSITION AND METHOD FOR CONTROLLING PEST - The present invention provides a composition having an excellent controlling activity on a pest. The composition comprising a compound represented by Formula (1) and one or more pyrethroid compound(s) selected from Group (A) shows an excellent controlling activity on a pest. Group (A): a group consisting of acrinathrin, bifenthrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lamda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, deltamethrin, etofenprox, fenpropathrin, fenvalerate, esfenvalerate, flucythrinate, fluvalinate, tau-fluvalinate, halfenprox, permethrin, protrifenbute, silafluofen, tefluthrin and tralomethrin07-25-2013
20090275533FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS - Fused bicyclic pyrimidine compounds of formula (I):11-05-2009
20120022021Mixtures of strobilurins with 1-methylcyclopropene - The present invention relates to mixtures comprising 01-26-2012
20120028920DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS - A heterocyclic compound or a salt thereof represented by the formula (1):02-02-2012
20120028919PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS - The present invention provides a compound of formula I02-02-2012
20130196950RETINOID REPLACEMENTS AND OPSIN AGONISTS AND METHODS FOR THE USE THEREOF - Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.08-01-2013
20130196951USE OF NITRIC OXIDE TO ENHANCE THE EFFICACY OF SILVER AND OTHER TOPICAL WOUND CARE AGENTS - The present invention is directed to compositions comprising at least one nitric oxide donor and at least one second therapeutically active agent with antimicrobial or wound healing capability. In one embodiment, the nitric oxide donor is a nanoparticle which is designed to control for the amount and duration of release of nitric oxide. The nanoparticle may further comprise the additional therapeutically active agent. The composition is useful for enhancing wound healing and for treating and preventing microbial infection. In one embodiment, the composition is directed toward reducing oral bacteria or dental plaque. The combination of one or more nitric oxide donors and one or more additional therapeutically active agent results in unexpected synergistic effects, wherein both the antimicrobial efficacy of the nitric oxide and the antimicrobial or wound healing efficacy of the second therapeutically active agent are enhanced. As a result, a patient may benefit from reduced dosage requirements and a reduced likelihood of antimicrobial resistance. The composition may be formulated for local or systemic administration, for topical applications as well as for use in coatings for medical supplies and devices.08-01-2013
20120077777NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY - The present invention relates to a compound of following formula (I):03-29-2012
20120077775MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 - Disclosed are macrocyclic compounds of formulae I-V, which are analogs of the pochonin resorcylic acid lactones, and processes for the preparation of the compounds. The compounds disclosed are useful as inhibitors of kinases and Heat Shock Protein 90 (HSP 90). Also disclosed are pharmaceutical compositions comprising an effective kinase-inhibiting amount or an effective HSP90-inhibiting amount of the compounds and methods for the treatment of disorders that are mediated by kinases and HSP90.03-29-2012
20120094956Treatment of Cancer with Specific RXR Agonists - A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.04-19-2012
20130210767BIOCIDAL COMPOSITION AND METHOD - An aqueous biocidal composition comprising: (a) a compound of formula (II): or a derivative salt thereof wherein L is a linking group; each of R08-15-2013
20130210768POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 - The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.08-15-2013

Patent applications in class Silicon containing DOAI